Aethlon Medical agrees all-stock merger with North Immunology

• Aethlon Medical agreed to an all-stock merger with privately held North Immunology, combining operations under the North Immunology name.
• The combined company is expected to trade on Nasdaq under ticker NRTX, replacing Aethlon’s current listing.
• A concurrent oversubscribed private placement is expected to raise about USD 180 million gross, including conversion of about USD 34 million in convertible promissory notes.
• Proceeds are expected to fund operations into the second half of 2028, centered on NOR-101 for atopic dermatitis.
• NOR-101 Phase 1a is slated for Q1 2027, with interim PK and safety by mid-2027; Phase 1b and Phase 2b topline data targeted in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609170630PR_NEWS_USPR_____LA50452) on September 17, 2026, and is solely responsible for the information contained therein.